Acute Lymphoblastic Leukemia Clinical Trials

113 recruiting

Acute Lymphoblastic Leukemia Trials at a Glance

282 actively recruiting trials for acute lymphoblastic leukemia are listed on ClinicalTrialsFinder across 6 cities in 58 countries. The largest study group is Phase 2 with 128 trials, with the heaviest enrollment activity in Houston, Duarte, and Seattle. Lead sponsors running acute lymphoblastic leukemia studies include City of Hope Medical Center, The First Affiliated Hospital of Soochow University, and Institute of Hematology & Blood Diseases Hospital, China.

Browse acute lymphoblastic leukemia trials by phase

Treatments under study

About Acute Lymphoblastic Leukemia Clinical Trials

Looking for clinical trials for Acute Lymphoblastic Leukemia? There are currently 113 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Lymphoblastic Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 282 trials

Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled80 locationsNCT06137118
Recruiting
Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814
Recruiting
Phase 2

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital128 enrolled2 locationsNCT06533748
Recruiting
Phase 4

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital850 enrolled3 locationsNCT06289673
Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled109 locationsNCT04521231
Recruiting
Phase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06390319
Recruiting
Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center33 enrolled1 locationNCT06195891
Recruiting
Phase 3

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen304 enrolled192 locationsNCT04994717
Recruiting
Early Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia
City of Hope Medical Center15 enrolled1 locationNCT06735690
Recruiting
Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)222 enrolled144 locationsNCT06124157
Recruiting
Phase 2

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

ObesityAcute Lymphoblastic Leukemia
St. Jude Children's Research Hospital20 enrolled1 locationNCT07228741
Recruiting
Phase 3

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology310 enrolled461 locationsNCT03150693
Recruiting
Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)153 enrolled108 locationsNCT06317662
Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Not Applicable

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Acute Lymphoblastic Leukemia, Pediatric
Roswell Park Cancer Institute100 enrolled1 locationNCT06074666
Recruiting
Phase 1

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid LeukemiaT-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Lymphoma
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05995028
Recruiting

Childhood Cancer Survivors' Affective Response to Exercise

Acute Lymphoblastic LeukemiaALL, Childhood
St. Jude Children's Research Hospital125 enrolled1 locationNCT05763290
Recruiting
Phase 2

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Wugen, Inc.125 enrolled12 locationsNCT06514794
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 2

Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaTransplantation, Stem Cell+1 more
The First Affiliated Hospital of Soochow University48 enrolled1 locationNCT06816134